Multiple Myeloma

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

The FDA issued a complete response letter to Spectrum Pharmaceuticals, informing the company that its new drug application (NDA) for the use of Captisol-enabled melphalan in multiple myeloma will not be approved in its current form.

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

The FDA has granted a priority review designation to carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

The FDA has assigned a priority review designation to daratumumab for heavily pretreated patients with multiple myeloma.

The European Commission has approved panobinostat in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory multiple myeloma following prior treatment with bortezomib and an immunomodulatory agent.

Sarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.

The FDA has granted elotuzumab (Empliciti) a priority review for use in combination therapy in pretreated patients with multiple myeloma.

Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.

The European Medicines Agency has accepted a marketing authorization application for ixazomib in combination with lenalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma.

Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.